ストックスクリーナーアプリを入手
49.63
0.72%
-0.365
前日終値:
$50.00
開ける：
$50.1
24時間の取引高:
7.19M
Relative Volume:
0.61
時価総額：
$100.74B
収益：
$48.30B
当期純損益:
$-8.95B
株価収益率:
-11.23
EPS:
-4.42
ネットキャッシュフロー:
$13.94B
1週間 パフォーマンス:
-7.63%
1か月 パフォーマンス:
-15.88%
6か月 パフォーマンス:
-6.99%
1年 パフォーマンス:
+2.86%
1日の値動き範囲:
$49.22
$50.40
1週間の範囲:
$44.93
$53.42
52週間の値動き範囲:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
49.64 | 100.74B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
737.56 | 667.64B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
154.13 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
171.13 | 308.39B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
63.33 | 281.01B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.70 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol Myers Squibb (BMY) Partners with Optellum for AI Lung Ca - GuruFocus
Bristol Myers' heart disease drug fails to meet main goals in late-stage study - Reuters
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Bristol Myers stumbles in bid to widen heart drug’s use - BioPharma Dive
BMO maintains Bristol-Myers $61 target after trial setback By Investing.com - Investing.com India
Bristol-Myers stock dips on trial results - Investing.com Australia
BMS’ Camzyos fails to show new cardiomyopathy benefit in Phase III - PharmaLive
OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra - 01net
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III - BioSpace
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis - Quantisnow
Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires? - Insider Monkey
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
BMS Phase III Camzyos trial misses endpoints - The Pharma Letter
Chemotherapy Market Overall Study Report 2025-2032 | - openPR.com
Bristol Myers (BMY) Reports Unmet Goals in Key Trial for Camzyos - GuruFocus
Bristol Myers falls as heart disease drug fails in late-stage trial - TradingView
Bristol Myers reports setback in Camzyos heart drug trial - Investing.com
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsight - The Globe and Mail
Bristol Myers: new approval for Opdivo+Yervoy - MarketScreener
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week - MedCity News
Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuit - Medical Dialogues
Bristol Myers Squibb (BMY) Secures FDA Approval for Liver Cancer Treatment - GuruFocus
UBS cuts Bristol-Myers Squibb price target to $54 from $60 By Investing.com - Investing.com South Africa
Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods - insights.citeline.com
Bristol-Myers Squibb Faces Q1 Expectations With Eliquis And Revlimid Leading - Finimize
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? - Insider Monkey
Bristol Myers combo follows Roche, AstraZeneca immunotherapy rivals into first-line liver cancer - Fierce Pharma
UBS cuts Bristol-Myers Squibb price target to $54 from $60 - Investing.com Australia
Here's What To Expect From Bristol-Myers Squibb's Next Earnings Report - Barchart.com
Dasatinib Drugs Market Deep Research 2025-2032 | Bristol-Myers - openPR.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
10 Best Medical Stocks to Buy According to Billionaires - Insider Monkey
Bristol Myers Squibb Posts 3Q Sales Growth as R&D Spending Rises - MarketScreener
FDA Approves Opdivo (BMY) Plus Yervoy Combo for Colorectal Cance - GuruFocus
About us - Bristol Myers Squibb
Bristol Myers Beats Pomalyst Antitrust Suit Alleging IP Fraud - Law360
Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today - Yahoo Finance
Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in - Insider Monkey
Bristol Myers Freed From Blood Cancer Drug Antitrust Litigation - Bloomberg Law News
Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy - Yahoo Finance
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo - TradingView
Bristol-Myers Squibb Co (BMY) Trading Down 4.32% on Apr 9 - GuruFocus
Bristol Myers Squibb Co. Enters Oversold Territory - Nasdaq
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients - Benzinga
Bristol Myers (BMY) Prevails in Antitrust Case Over Pomalyst - GuruFocus
Bristol Myers: FDA approves Opdivo + Yervoy combination - MarketScreener
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly - Reuters
Bristol-Myers Squibb (BMY) Downgraded by Goldman Sachs Amid Reve - GuruFocus
Bristol Myers Squibb (BMY) Gains FDA Approval for Cancer Treatme - GuruFocus
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
1.64%
0.37%
大文字化:
|
ボリューム (24 時間):